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Abstract
Background: Patient preferences are key parameters to evaluate benefit-harm balance of statins for primary
prevention but they are not readily available to guideline developers and decision makers. Our study aimed to elicit
patient preferences for benefit and harm outcomes related to use of statins for primary cardiovascular
disease prevention and to examine how the preferences differ across economically and socio–culturally different
environments.
Methods: We conducted preference-eliciting surveys using best-worst scaling designed with a balanced incomplete-
block design (BIBD) on 13 statins-related outcomes on 220 people in Ethiopia and Switzerland. The participants made
tradeoff decisions and selected the most and least worrisome outcomes concurrently from each scenario generated
using the BIBD. The design yielded 34,320 implied paired-comparisons and 2860 paired-responses as unit of analysis for
eliciting the preferences that were analyzed using a conditional-logit model on a relative scale and surface under the
cumulative ranking curve from multivariate random-effects meta-analysis model on a scale of 0 to 1.
Results: There was high internal consistency of responses and minimal amount of measurement error in both surveys.
Severe stroke was the most worrisome outcome with a ceiling preference of 1 (on 0 to 1 scale) followed by severe
myocardial infarction, 0.913 (95% CI, 0.889–0.943), and cancer, 0.846 (0.829–0.855); while treatment discontinuation, 0.090
(0.023–0.123), and nausea/headache, 0.060 (0.034–0.094) were the least worrisome outcomes. Preferences were similar
between Ethiopia and Switzerland with overlapping uncertainty intervals and concordance correlation of 0.97 (0.90–0.99).
Conclusions: Our study provides much needed empirical evidence on preferences that help clinical guidelines consider
for weighing the benefit and harm outcomes when recommending for or against statins for primary prevention of
cardiovascular disease. The preferences are consistent across the disparate settings; however, we recommend inclusion of
more countries in future studies to ensure the generalizability of the preferences to all environments.
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Background
Statins are among the most widely used drugs for pri-
mary and secondary prevention of cardiovascular disease
(CVD) [1]. Current clinical guidelines have progressively
lowered the threshold to initiate statins for primary pre-
vention to 7.5–10% 10-year risk for CVD [2]. As a result,
millions of healthy people may be indicated for statins as
life-long medication. According to the American College
of Cardiology/American Heart Association guideline, for
example, 24% of the U.S. population is ought to use sta-
tins [3]. Until recently, the use of statins has been lim-
ited to affluent regions despite the fact that three-
fourths of global CVD deaths occur in low- and middle-
income countries [4, 5]. However, the recently improved
availability of less expensive generic statins has made
them widely accessible to the developing world as
well [6].
In spite of their wider use, it is remarkable that exist-
ing clinical guidelines do not explicitly assess whether
the harms related to statins are trivial enough to be ig-
nored or offset their benefits [7]. Randomized controlled
trials (RCTs) have shown statins’ efficacy in reducing risk
of new CVD but also reported harmful effects, such as
type 2 diabetes, cancer, and hepatic and renal dysfunc-
tions [8, 9]. Clinical guidelines heavily rely on relative ef-
fects of statins, which alone cannot justify their use [1,
10]. It is essential to take into account absolute risks of
benefit and harm outcomes related to the drugs calcu-
lated from the number of prevented outcomes or caused
harmful events in people taking statins versus people
not taking statins [11]. Moreover, considering social con-
text and people’s preferences is fundamental to move
forward to informed medical practices [12]. Some out-
comes are more important than others according to the
preferences of individuals and thus need to be weighted
accordingly when estimating the benefit-harm balance of
statins and framing recommendations. Advanced
methods that analyze all key parameters–relative effect
size, baseline risk and preferences–to quantitatively as-
sess benefit-harm balance have become available that go
far beyond the number needed to treat and number
needed to harm [11, 13].
While evidence on treatment effects and baseline risks
is fairly available, evidence on the preferences, which is a
defining parameter to perform benefit-harm analysis, is
mostly lacking [14]. Some studies, including the Euro-
pean and Global Burden of Diseases (GBD), aiming at
measuring disability-adjusted life-years (DALYs), esti-
mated disability weights–similar to preference weights–
for a wide array of diseases [15, 16]. These estimates,
however, lack specificity with respect to certain clinical
decision contexts, as in the case of prescribing statins
for primary prevention of CVD. Furthermore, prefer-
ences may vary across populations living in different
health systems and social-cultural environments, which
may have a substantial impact on the benefit-harm bal-
ance of statins and guideline developments [15, 17]. In
light of these, we aimed to elicit preferences for benefit
and harm outcomes related to the use of statins with
emphasis on primary prevention of CVD, and compare
preferences between two populations in Sub-Saharan Af-
rica and Europe who live in greatly differing settings in
terms of health systems and socio-cultural perspectives.
Methods
Study design and participants
We conducted a preference-eliciting survey in Mekelle,
Ethiopia, and Zurich, Switzerland from September to
December 2016. We considered these environments that
differ in terms of health system, socio-cultural and eco-
nomical statuses, and hence to serve well for comparison
of the preferences. Participants had to be 40 years or
older and without a history of CVD events. We did not
apply any other in- or exclusion criteria.
We obtained the preferences on the predetermined sa-
lient benefit and harm outcomes related to statins in the
survey using face-to-face interviews. In Ethiopia, the sur-
vey was conducted on a home-to-home basis whose re-
spondents were sampled using a computer-assisted
random number generator from an existing sampling
frame designed for a WHO-stepwise survey. The ran-
domly selected households were visited at convenient
times and revisited up to three times when the eligible
respondents were not available. The respondents were
provided a mobile card for their time that was worth
CHF 2.50, an amount equivalent to the market value of
the compensation provided in Switzerland. In Zurich, we
invited participants from people who visited the travel
clinic of the University of Zurich. The walk-in clinic ren-
ders service of pre-travel advice on preventive measures
including vaccinations, to around 20,000 travelers each
year. We considered the setting of the travel clinic to pro-
vide a good source for recruitment of participants since
the demographic profile of visitors to the clinic is similar
to that of the Swiss general population [18]. We thus pre-
sumed that these individuals represent the general popula-
tion quite well. The study participants were interviewed
face-to-face. They were compensated with a free consult-
ation at the travel clinic that was worth CHF 50.
Questionnaire design and procedure
We designed our study to yield preference weights for a
higher-level decision–i.e., to help clinical guideline devel-
opers to assess benefit-harm balance of statins, for which
knowledge about preference is essential. Since guideline
developers have to rely on the published evidence on the
effectiveness of statins, we decided to include 13 statin-
associated benefit ad harm outcomes in the survey that
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were reported in RCTs/meta-analyses [8, 9, 19, 20]. The
starting point for measuring preferences is a clear defin-
ition of the outcomes to be measured because the differ-
ent outcomes have wide spectrum of manifestation. For
example, the statin-associated muscle adverse effects have
ranges of presentation from myalgia to rhabdomyolysis
[21]. In addition, the participants may not be equally fa-
miliar with the medical terms and thus could have differ-
ent perceptions on the outcomes, which would influence
eliciting the preferences [12]. Hence, we used specific lay
descriptions for each outcome, instead of the medical
terms, which were constructed as a function of health
loss–clinical features, treatment modalities, and functional
consequences or prognosis–on which the respondents re-
lied to express their preferences (Additional file 1). We
tried to simulate a typical manifestation for each outcome
while being fully aware that this simplifies reality. We con-
sulted clinical and methods experts to evaluate the lay de-
scriptions. We stated the descriptions using as little
technical terms as possible and supplemented anonymous
pictures that would help respondents easily select their
preferred outcome.
We originally developed the questionnaire in English
and then translated it into Tigrigna and German–the local
languages in the respective study sites. We consulted bi-
lingual speakers and experts familiar with preference stud-
ies to check for consistency and appropriateness of the lay
descriptions. We piloted the questionnaires twice in both
sites, first on 20 individuals and then on 10 others in the
second round of the pilot that helped rephrase the vi-
gnettes of the outcomes, and simplify the medical terms.
Members of the research and additionally recruited health
personnel conducted the interviews. The recruits were
trained, overseen, and assisted when the need arose.
The preference questions were designed using the ob-
ject case Best-Worst Scaling (BWS) method [22], by
which participants had to select a pair of best and worst
outcomes at a time from presented scenarios. The BWS
measures utility or preferences efficiently from fewer re-
spondents. It overcomes the methodological and psycho-
metric weakness of other methods, including visual
analogue scale (VAS), pair comparisons, and time trade-
off [23, 24]. In our study, the terms ‘best’ and ‘worst’
refer to the most and least worrisome clinical outcome,
respectively. We used the Balanced Incomplete Block
Design (BIBD) to get efficiently designed choice sets
(Additional file 1). This provided 13 scenarios, with four
outcomes in each scenario, to be answered per respond-
ent, where every outcome appeared in four different sce-
narios and coexisted with another one just once. This
design yielded 2860 paired-responses and 34,320 implied-
comparisons in the pooled data.
Before they started the BWS procedure, respondents
were asked to express their perceived severity using VAS
for each of the 13 outcomes in order to familiarize them
with the descriptions. This also offered a comparison of
the preferences from the VAS with BWS.
Mekelle University, Ethiopia and the University of
Zurich granted the study an expedited approval. The study
did not involve any physical or laboratory examination,
nor did it collect any respondents’ identifiers, and thus we
obtained oral consent from each participant after they
were briefed about the study’s purpose and procedure, and
as well as the confidentiality of the anonymized data.
Sample size
There is no standard sample size estimation method for
BWS studies [25]. We reviewed studies that used BWS
and took the median sample size of 220 (this included
10% contingency for non-responses) from studies with
similar number of choice sets [22, 26].
Statistical analysis
We used R (3.2.2) and STATA (13.0) for data analyses
and SAS (9.4) to generate the BIBD. First, we used R al-
gorithms to convert the respondents’ dataset into struc-
turally convenient data frame for preference analyses.
We assigned 1 for an outcome selected as most worri-
some, − 1 for least worrisome, and 0 unless selected
otherwise.
We estimated the preferences in log-transformed coef-
ficients (log-odds) and probability terms using different
analysis ways; thereafter, we refer to these as relative
preferences, and preference weights, respectively. We
ran conditional logit-regression models on the 34,320,
18,720, and 15,600 paired-comparisons on the pooled
and survey-specific data to get the relative preference
values for the outcomes. Unlike standard analyses, this
method modeled response as a function of differences in
preferences, that indicates utility or preference relations
[27] and took into account the correlation of responses
within an individual and a scenario. The result from this
method explains the relationship with microeconomic
theory, which has implications for statistical inference
[28]. The model yields preferences on log-scaled linear
line on which the different outcomes take relative posi-
tions that imply their relative preferences or importance.
We also estimated preferences weights in probability
terms; i.e., the probability of an outcome being selected
as most worrisome given the rest comparators. First we
calculated standardized mean of frequencies of outcome
selected as ‘best’ minus ‘worst’ (B–W) scores and stand-
ard deviation for each pair of responses. We then ran
multiple treatment comparison method (i.e., multivariate
random-effects meta-analysis model) on the outcomes
to obtain summary of standardized mean differences for
the B–W scores for each outcome. With flat priors and
posterior normal distribution of the standardized mean
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difference of B–W scores for each pair of responses and
variance equal to the frequentist estimates from the
above results, we calculated the probability that an out-
come is selected as the most worrisome, the second wor-
risome, and so on using Markov chain Monte Carlo
method in the Bayesian model. This yielded the prob-
ability of being most worrisome for each outcome in
every trial. We then estimated the surface under the cu-
mulative ranking curve for each outcome in probability
terms as shown in Fig. A of the Additional file 1. A
preference weight of 1 means that the outcome is
certain to be the most worrisome while 0 corresponds
to the outcome to be the least worrisome. To esti-
mate confidence intervals, we simulated normal ran-
dom variates with means defined by the preference
weights and variance by the between survey estimates.
We then drew 1000 bootstrap samples and repeated
the means for each sample. We took the 2.5th and
97.5th percentiles in the distribution about each pref-
erence weight.
We assessed measurement error and internal
consistency within and between the surveys by portray-
ing a heat map of response probability for the 13 × 13
paired-comparisons. We also ran linear regression to test
if survey site and socio-demographic factors affected the
preferences.
Results
Characteristics of respondents
We obtained responses from all the 220 participants.
Table 1 shows socio-demographic and other characteris-
tics of respondents by survey site. Respondents from
Switzerland had a higher proportion of educational at-
tainment and employment than those from Ethiopia.
While age distribution was truncated by sampling eligi-
bility at 40 years, the participants were older and the
probability of morbidity was higher in Switzerland.
Consistency of responses
Figure 1 shows heat maps of probability for the 13 × 13
possible combinations of outcomes for the survey-
specific data. Each cell indicates the probability that re-
spondents selected the first comparator in a pair as the
most worrisome. The matrix of the probabilities is ar-
ranged from 0 to 1, which corresponds to yellow and or-
ange, respectively. The smooth transition from yellow at
the right lower corner to orange at the left upper corner
of the map indicated a small amount of measurement
error and high internal consistency of the responses
within and between the sites. In support to this, we in-
cluded a question that asked respondents how difficult
the descriptions and the BWS procedure were to under-
stand. Eighty four percent (84/100) of the respondents
in Ethiopia and 96% (115/120) in Switzerland reported
that they well understood the questions and the proce-
dures of the study; where this slight difference corre-
sponded to the slightly less consistency on the heat map
from Ethiopia.
Preferences
The relative preference values (log-odds) of the out-
comes compared to the treatment discontinuation along
with 95% CI’s are shown in Table 2. Severe stroke, severe
myocardial infarction (MI), and cancer were the three
most worrisome outcomes. The least worrisome out-
comes were treatment discontinuation and nausea/head-
ache. The orders of the relative preferences of all
outcomes were consistent across the three models (cor-
responding to the surveys in Ethiopia, Switzerland and
the pooled data) with precise confidence intervals. Since
relative scales are not appropriate for comparison, we
normalized the values and found that the preferences
were similar between Ethiopia and Switzerland. On the
relative scale, two point estimates showed reversal in
order; i.e., in Ethiopia, heart failure was preferred to
moderate MI, and acute kidney failure to unstable an-
gina as compared to the Swiss data. However, the uncer-
tainty intervals ruled out the possibility of flip of orders.
The uncertainty intervals of the survey-specific data in-
cluded the null value for nausea/headache, which sug-
gest respondents had similar preferences for nausea/
headache and the treatment discontinuation. In the
pooled data, the interval did not contain the null value
probably due to the doubled sample size.
The preference weights in probability terms are pre-
sented in Table 2. In the models run on the pooled and
separate surveys, the preference weights were patterned
in a similar way as the orders in the relative scale, and
with close magnitudes between Ethiopia and
Switzerland. In the pooled data, severe stroke outranked
all with preference of 1 followed by severe MI, 0.913
(95% CI 0.889–0.942); cancer, 0.846 (0.829–0.855); mod-
erate stroke, 0.735 (0.671–0.802); and moderate MI, 0.
664 (0.611–0.715); whereas nausea/headache, 0.060 (0.
034–0.094); treatment discontinuation, 0.090 (0.023–0.
123); and myopathy, 0.230 (0.228–0.238) were the least
worrisome outcomes.
We checked the measurement agreement between
methods, and the consistency of respective results be-
tween the survey sites. Figure 2 shows that the relative
preferences, standardized B–W scores and preference
weights were linearly related as depicted by the rela-
tional line and the corresponding increase in circle areas.
Figure 3 presents observed preferences with a local
smoothing over survey-specific versus pooled data using
different preference scales. The results were consistent
between the survey data with overlapping uncertainty
intervals of estimates from the linear regression
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(Additional file 1) and high Lin’s Concordance Correl-
ation Coefficient between the pooled and survey-specific
data, 0.98 (95% CI 0.97 to 0.99) for the normalized log-
odds and 0.97 (95% CI 0.90–0.99) for both preference
weights and standardized B–W scale. Plot ‘d’ presents
poor relationship of VAS versus preference weights. The
Concordance Correlation Coefficient between these
measures was 0.68 (95% CI 0.40–0.85) that indicated
VAS was a weak method to quantify preference values.
Reasons most frequently mentioned for influencing re-
spondents’ preference were prognosis, 28% (126 out of
450 responses); severity, 27% (122/450); and curability,
21% (95/450) of the clinical outcomes. The linear
regression did not find factors with consistent pattern of
influence on the preferences (Additional file 1).
Discussion
Summary of results
We found in this study that preferences of respondents
from Ethiopia and Switzerland were similar despite large
differences in the socio-cultural, health system, and eco-
nomic contexts. Severe stroke, severe MI and cancers
were ranked the worst outcomes while myopathy, nau-
sea/headache, and treatment discontinuation were per-
ceived as the least worrisome outcomes.
Table 1 Characteristics of participants involved in the preference eliciting study
Characteristics Pooled (n = 220) Ethiopia (n = 100) Switzerland (n = 120)
Sex
Male, n(%) 111 (50.4) 54 (54.0) 57 (47.5)
Female 109 (49.6) 46 (46.0) 63 (52.5)
Age
Mean (SD) 52.9 (0.6) 49.7 (0.7) 55.6 (0.8)
40–64 195 (88.6) 96 (96.0) 99 (82.5)
≥ 65–81 25 (11.4) 4 (4.0) 21 (17.5)
Education
Mean in years (SD) 10.12 (0.4) 6.55 (0.6) 13.1 (0.4)
None 25 (11.4) 25 (25.0) 0
Primary 46 (20.9) 42 (42.0) 4 (3.3)
Secondary 70 (31.8) 16 (16.0) 54 (45.0)
Higher 79 (35.9) 17 (17.0) 62 (51.7)
Job
Salaried 107 (48.2) 35 (35.0) 71 (59.2)
Own business 46 (20.9) 24 (24.0) 22 (18.3)
Pensioned 28 (12.7) 4 (4.0) 24 (20.0)
No job 39 (18.2) 37 (37.0) 3 (2.5)
Current or previous statin users 20 (9.1) 8(8.0) 12(10.0)
Co-living person
Alone 48 (21.8) 11 (11.0) 37 (30.8)
Family 171 (78.2) 89 (89.0) 83 (69.2)
Respondents understand the
content and procedure of
the questionnaire
Strongly agree 83 (37.7) 7 (7.0) 76 (63.4)
Agree 116 (52.7) 77 (77.0) 39 (32.5)
Neither 20 (9.1) 16 (16.0) 4 (3.3)
Disagree 1 (0.5) 0 1 (0.8)
Morbidity
None 149 (67.7) 81 (81.0) 68 (56.7)
Yes a 71 (32.3) 19 (19.0) 52 (43.3)
aHypertension, type 2 diabetes, join/muscle disease, cancer, psychiatric disease were most frequently reported
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Interpreting and discussing the findings in comparison
with the literature
Although the universality of preference weights across
culturally, and socio-economically diverse environments
is much discussed in the literature [15], our study found
consistent preferences for the outcomes between the
study sites taken from the Sub-Saharan African and
European regions. Indeed, the GBD study that involved
wide ranges of clinical outcomes did not show substan-
tially variation of preferences across social contexts [15].
The hypothesis of preference weight variations across
settings may stem from previous approaches that had
used welfare loss to define the weights instead of health
loss [29, 30]. Quantifying preferences with an aim to
measure welfare loss is likely to be affected by a society’s
level of welfare such as wealth and availability of health
insurance. On that account, we predicated that cost or
affordability, which greatly varies across the study areas,
should not be regarded as a decisive outcome to influ-
ence statin prescribing decision because this could bias
preferences of people from less affluent regions [31, 32].
Clinical guidelines emphasize on health loss, not welfare
loss. Cost of treatment should be managed in a different
way once it is established that net benefit of statins out-
weighs their harms. We controlled potential influences
that may contribute to response variation within and
across societies by specifying clear constructs of the clin-
ical outcomes in order to ease, standardize, and decrease
ambiguity of preference measurements among the par-
ticipants with varying individual characteristics, such as
educational level and awareness. This might have helped
attenuate possible inter-personal or cross-environmental
preference discrepancies.
We expected a wide range of preference magnitudes
between the outcomes and, indeed, we found greatly dis-
tinct preference weights in our study ranging from 1 for
severe stroke and 0.060 for nausea and headache in the
pooled data. The preferences of the other outcomes
spread out in between. In the context of prescribing de-
cision, this suggests that severe stroke is the most worri-
some and that patients may opt to take statins to
prevent risk of severe stroke at the expense of possible
unwanted effects. At policy level, these greatly differing
values imply that clinical guidelines need to consider the
preference values to quantitatively measure the benefit-
harm balance of outcomes related to statins. We also
presented alternative measures in term of a relative scale
to be used in similar way for gradating the importance
of the outcomes. For instance, severe stroke was about
six times more important than nausea/headache or treat-
ment discontinuation. However, relative scales should
not be used to compare the preferences between samples
or varying settings, unless they are normalized.
We compared our results with the disability weights
published by the European and GBD studies although
estimates from these studies are less likely to apply to
specific clinical decision-making contexts [15]. The
weight for severe stroke, for example, was 0.539 in the
GBD study, which significantly differs from the weight
we obtained (i.e., 1.00). These studies estimated disability
weights for a wide array of diseases and injuries with the
aim of measuring DALYs [15]. They compared a given
disease with another random disease with high chance
of that disease being paired with another more severe
one. Consequently, some moderate diseases could get
higher weights if randomly paired with a milder, or
lower if paired with a severe one, which would to a
spurious conclusion. It was not also possible in the GBD
study to compare all diseases relative to one another and
that the method used could not handle the comparisons
in an efficient way [33]. Furthermore, such weights could
not be used for all clinical decision-contexts because
0.00
0.25
0.50
0.75
1.00
Prob.
EthiopiaSwitzerland
Fig. 1 Heat maps indicating consistency of responses. The heat maps show the probability of being selected as most worrisome of each
comparison for the 13 × 13 possible combinations of the outcomes. Each cell indicates the probability that the respondents selected the first
comparator in a pair as most worrisome. The matrix of the probability is arranged from zero to one, which corresponds to yellow and orange
colors, respectively. Except few randomly assorted colors, the visually smooth transition from yellow at the right lower corner to orange at the left
upper corner of the maps indicates a small amount of measurement error and high internal consistency. The white patches indicate there were
no actual responses corresponding to the pairs; note that this doesn’t mean non-response
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they could be different if a different decision context is
considered, like the statin prescribing scenario, in which
preferences are influenced by the number, clinical fea-
ture and prognosis of the considered outcomes. For ex-
ample, there are only about a dozen statin-associated
benefit and harm outcomes on which individuals depend
to make preference tradeoffs. As a result, the expected
preference weights of these outcomes simply cannot be
similar with those calculated for other purposes and de-
cision contexts, such as for measuring DALY in the
GBD study where many outcomes were considered.
Implications of findings
The preference weights calculated in our study have im-
portant implications for guideline developers and clini-
cians. No empirical evidence about preferences is
available for the statin-associated benefit and harm out-
comes and thus clinical guideline developers did not
consider when framing the clinical guideline of statins
for CVD prevention. There is also a lack of quantitative
evaluations of the benefit-harm balance of statins that
would needs to include patient-important outcomes, the
effects of statins on these outcomes, baseline incidences
of the population of interest to calculate absolute effects
as well as preference weights for different outcomes [1,
34]. Ignoring preferences and baselines risks could lead
to over treatment, especially in primary population
where the risk of CVD is low and uncertain. Our study
provides preferences values of the outcomes that are
much needed for quantitatively assessing the benefit and
harm balance of statins. The greatly differing preference
values among the outcomes may also give clinicians
some guidance for considering patients’ preferences
when prescribing statins, and as well as baseline evi-
dence to researchers to develop personalized benefit-
harm assessment models.
Strengths and limitations of the study
Our study has a number of strengths. We clearly defined
our decision-context and constructed the descriptions of
the clinical outcomes and the answering options in an it-
erative way to make sure respondents understand them
and give us valid preferences. Also, we employed face-
to-face interviews to enhance data quality and minimize
non-response rate. We pursued efficient methods for
comparing all outcomes relative to each other from
fewer respondents and analyzed the data with robust
methods. Another key strength was testing the hypoth-
esis on possible variation in the preference weights
across divergent environments, which is critical in decid-
ing whether setting-specific prescribing practices are
needed.
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Moderate MI
Heart failure
DM type 2Liver injury
Unstable angina
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Fig. 2 Relationships of preference measurement methods. The smoothed line and increase in circle size portray the relationship between the
preference measures
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Our study might also have certain limitations regard-
ing the preference estimates. The study sites were not
randomly selected. Although we tried to design the tool
in a way people would give their preference responses
emphasising on the lay descriptions regardless of differ-
ences in socio-demographic backgrounds, our data could
not rule out the possibility of getting different estimates
if we had included other sites. Besides since the descrip-
tions were as short as possible, respondents might give
responses based on own perceptions out of the scope of
the specified lay descriptions. Generally, there was high
internal consistency and low measurement errors, except
a few erratic paired-responses from both sites, which
may show that a few respondents were skeptical or gave
responses based on their perception independent of the
lay descriptions.
Conclusions
Our study provides much needed evidence on preferences
related to statins for primary CVD prevention that clinical
guideline developers could take into account when devel-
oping recommendations. Contrary to popular opinion,
our empirical data show that preferences were similar
across environments that greatly differ in terms of demo-
graphic, socio-cultural and economical perspectives. How-
ever, we recommend inclusion of more countries in future
studies to make robust conclusion about generalizability
of the preferences to more environments.
Additional file
Additional file 1: This contains an example lay description for chest pain,
BIBD design of outcomes, surface under the cumulative ranking curves of
benefit and harm outcomes as measure of the preferences, and results of
linear regression assessing influence of participants’ characteristics on
preference values. (PDF 376 kb)
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